{
    "functional_evidence_assessment": [
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "G",
                    "alt": "S",
                    "position": "2019"
                },
                "variant_string_id": "LRRK2 G2019S"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Autosomal dominant mutations in the human Leucine - Rich Repeat Kinase 2 (LRRK2) gene are the most common monogenetic cause for Parkinson disease (PD). Several LRRK2 variants associated with PD exhibit increased kinase activity suggesting a gain - of - function mechanism, in which elevated kinase activity of LRRK2 triggers neurotoxicity and neurodegeneration. Additionally, apoptotic mechanisms have been described in mutant LRRK2 - mediated cell - death.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states that LRRK2 mutations are associated with PD, and the proposed disease mechanism is a gain - of - function due to increased kinase activity leading to neurotoxicity and apoptosis.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Kinase activity assays were performed to test the phosphorylation of MKKs by LRRK2. PD - associated LRRK2 variants having mutations within their kinase domain display a higher degree of activity towards MKK phosphorylation.",
                    "judgment": "Yes",
                    "reasoning": "The kinase activity assay effectively models the proposed gain - of - function disease mechanism by measuring the phosphorylation activity of LRRK2 variants on MKK substrates.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3a: Basic Controls and Replicates",
                    "extracted_paper_info": "For the comparison of different LRRK2 mutants, at least four independent data points were used for each mutant. The kinase dead variant of LRRK2, LRRK2 K1906M, served as a negative control. Equal loading of used substrate proteins was confirmed by Ponceau staining. LRRK2 levels were determined by probing the blots with monoclonal rat anti - LRRK2 antibodies.",
                    "judgment": "Yes",
                    "reasoning": "The paper used a kinase - dead LRRK2 (K1906M) as a negative control, and at least four independent data points (replicates) were used for each mutant.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3c: Variant Controls",
                    "extracted_paper_info": "The kinase activity of wild - type LRRK2 was compared to the disease - associated variants LRRK2 R1441C, LRRK2 G2019S and LRRK2 I2020T.",
                    "judgment": "Yes",
                    "reasoning": "Wild - type LRRK2 was used as a control, and disease - associated variants were compared, which can be considered as variant controls.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4a: Statistical Analyses",
                    "extracted_paper_info": "Differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA). Pair - wise comparison was performed by Tukey's post - hoc test.",
                    "judgment": "Yes",
                    "reasoning": "The paper used ANOVA and Tukey's post - hoc test for statistical analysis, which are sufficient to estimate or calculate OddsPath - related measures.",
                    "next_step_or_outcome": "Proceed to Sub - step 4c"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4c: Correlate OddsPath",
                    "extracted_paper_info": "The LRRK2 G2019S mutant shows a 3 - 4 - fold higher phosphorylation of MKK6 compared with wild - type LRRK2. The increase in MKK6 phosphorylation observed for this LRRK2 variant is in the same range as the increase in autokinase activity.",
                    "judgment": "Based on the increase in phosphorylation activity (3 - 4 - fold increase compared to wild - type), and assuming standard ACMG OddsPath thresholds, the OddsPath is likely to be in the moderate range (if we assume a positive relationship between phosphorylation fold - change and OddsPath).",
                    "reasoning": "The significant increase in phosphorylation activity indicates a relatively high OddsPath value. Since it is a 3 - 4 - fold increase, it is likely above the threshold for moderate evidence.",
                    "next_step_or_outcome": "PS3_moderate"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_moderate"
            },
            "overall_conclusion": "The functional evidence for LRRK2 G2019S is rated as PS3_moderate because the disease mechanism is clearly defined as a gain - of - function due to increased kinase activity in PD. The kinase activity assay is applicable to this mechanism. Basic controls, replicates, and variant controls were used. Statistical analyses were performed, and the 3 - 4 - fold increase in MKK6 phosphorylation compared to wild - type suggests a moderate OddsPath value for pathogenicity."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "I",
                    "alt": "T",
                    "position": "2020"
                },
                "variant_string_id": "LRRK2 I2020T"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Autosomal dominant mutations in the human Leucine - Rich Repeat Kinase 2 (LRRK2) gene are the most common monogenetic cause for Parkinson disease (PD). Several LRRK2 variants associated with PD exhibit increased kinase activity suggesting a gain - of - function mechanism, in which elevated kinase activity of LRRK2 triggers neurotoxicity and neurodegeneration. Additionally, apoptotic mechanisms have been described in mutant LRRK2 - mediated cell - death.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly states the disease mechanism related to LRRK2 mutations causing PD through a gain - of - function mechanism.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Kinase activity assays were performed to test the phosphorylation of MKKs by LRRK2. PD - associated LRRK2 variants having mutations within their kinase domain display a higher degree of activity towards MKK phosphorylation.",
                    "judgment": "Yes",
                    "reasoning": "The kinase activity assay is relevant to the proposed gain - of - function disease mechanism by measuring LRRK2's phosphorylation activity on MKK substrates.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3a: Basic Controls and Replicates",
                    "extracted_paper_info": "For the comparison of different LRRK2 mutants, at least four independent data points were used for each mutant. The kinase dead variant of LRRK2, LRRK2 K1906M, served as a negative control. Equal loading of used substrate proteins was confirmed by Ponceau staining. LRRK2 levels were determined by probing the blots with monoclonal rat anti - LRRK2 antibodies.",
                    "judgment": "Yes",
                    "reasoning": "The use of a kinase - dead negative control (K1906M) and at least four independent data points (replicates) meets the requirements.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3c: Variant Controls",
                    "extracted_paper_info": "The kinase activity of wild - type LRRK2 was compared to the disease - associated variants LRRK2 R1441C, LRRK2 G2019S and LRRK2 I2020T.",
                    "judgment": "Yes",
                    "reasoning": "Wild - type and other disease - associated variants were used as controls, which can be considered as variant controls.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4a: Statistical Analyses",
                    "extracted_paper_info": "Differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA). Pair - wise comparison was performed by Tukey's post - hoc test.",
                    "judgment": "Yes",
                    "reasoning": "The use of ANOVA and Tukey's post - hoc test indicates sufficient statistical analysis for OddsPath - related measures.",
                    "next_step_or_outcome": "Proceed to Sub - step 4c"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4c: Correlate OddsPath",
                    "extracted_paper_info": "LRRK2 I2020T shows only a slight, but significant, increase of about 1.5 - fold of wild - type activity in phosphorylating MKK6. The increase in MKK6 phosphorylation observed for this LRRK2 variant is in the same range as the increase in autokinase activity.",
                    "judgment": "Based on the 1.5 - fold increase in phosphorylation activity compared to wild - type, and assuming standard ACMG OddsPath thresholds, the OddsPath is likely to be in the supporting range (if we assume a positive relationship between phosphorylation fold - change and OddsPath).",
                    "reasoning": "The relatively small increase in phosphorylation activity suggests a lower OddsPath value, likely in the supporting range.",
                    "next_step_or_outcome": "PS3_supporting"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for LRRK2 I2020T is rated as PS3_supporting. The disease mechanism of LRRK2 - related PD as a gain - of - function is well - defined. The kinase activity assay is appropriate. Basic controls, replicates, and variant controls were used. Statistical analyses were carried out, and the 1.5 - fold increase in MKK6 phosphorylation compared to wild - type indicates a supporting OddsPath value for pathogenicity."
        },
        {
            "variant_id": {
                "Gene": "LRRK2",
                "Protein_Change": {
                    "ref": "R",
                    "alt": "C",
                    "position": "1441"
                },
                "variant_string_id": "LRRK2 R1441C"
            },
            "functional_evidence_aim": "Pathogenic",
            "assessment_steps": [
                {
                    "step_name": "Step 1: Define the disease mechanism",
                    "extracted_paper_info": "Autosomal dominant mutations in the human Leucine - Rich Repeat Kinase 2 (LRRK2) gene are the most common monogenetic cause for Parkinson disease (PD). Several LRRK2 variants associated with PD exhibit increased kinase activity suggesting a gain - of - function mechanism, in which elevated kinase activity of LRRK2 triggers neurotoxicity and neurodegeneration. Additionally, apoptotic mechanisms have been described in mutant LRRK2 - mediated cell - death.",
                    "judgment": "Yes",
                    "reasoning": "The paper clearly defines the disease mechanism associated with LRRK2 mutations in PD as a gain - of - function mechanism.",
                    "next_step_or_outcome": "Proceed to Step 2"
                },
                {
                    "step_name": "Step 2: Evaluate applicability of general classes of assay used in the field",
                    "extracted_paper_info": "Kinase activity assays were performed to test the phosphorylation of MKKs by LRRK2. PD - associated LRRK2 variants having mutations within their kinase domain display a higher degree of activity towards MKK phosphorylation.",
                    "judgment": "Yes",
                    "reasoning": "The kinase activity assay is relevant to the proposed gain - of - function disease mechanism by measuring LRRK2's phosphorylation activity on MKK substrates.",
                    "next_step_or_outcome": "Proceed to Step 3"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3a: Basic Controls and Replicates",
                    "extracted_paper_info": "For the comparison of different LRRK2 mutants, at least four independent data points were used for each mutant. The kinase dead variant of LRRK2, LRRK2 K1906M, served as a negative control. Equal loading of used substrate proteins was confirmed by Ponceau staining. LRRK2 levels were determined by probing the blots with monoclonal rat anti - LRRK2 antibodies.",
                    "judgment": "Yes",
                    "reasoning": "The use of a kinase - dead negative control (K1906M) and at least four independent data points (replicates) meets the requirements.",
                    "next_step_or_outcome": "Proceed to Sub - step 3c"
                },
                {
                    "step_name": "Step 3: Evaluate validity of specific instances of assays - Sub - step 3c: Variant Controls",
                    "extracted_paper_info": "The kinase activity of wild - type LRRK2 was compared to the disease - associated variants LRRK2 R1441C, LRRK2 G2019S and LRRK2 I2020T.",
                    "judgment": "Yes",
                    "reasoning": "Wild - type and other disease - associated variants were used as controls, which can be considered as variant controls.",
                    "next_step_or_outcome": "Proceed to Step 4"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4a: Statistical Analyses",
                    "extracted_paper_info": "Differences in phosphorylation levels were probed for statistical significance by analysis of variance (ANOVA). Pair - wise comparison was performed by Tukey's post - hoc test.",
                    "judgment": "Yes",
                    "reasoning": "The use of ANOVA and Tukey's post - hoc test indicates sufficient statistical analysis for OddsPath - related measures.",
                    "next_step_or_outcome": "Proceed to Sub - step 4c"
                },
                {
                    "step_name": "Step 4: Apply evidence to individual variant interpretation - Sub - step 4c: Correlate OddsPath",
                    "extracted_paper_info": "The Roc - domain mutant LRRK2 R1441C showed no significant alteration in its kinase activity.",
                    "judgment": "Based on the lack of significant change in kinase activity, the OddsPath is likely to be close to 1, which does not support a strong pathogenic evidence.",
                    "reasoning": "Since there is no significant change in kinase activity, the OddsPath is not likely to meet the thresholds for higher levels of pathogenic evidence.",
                    "next_step_or_outcome": "PS3_supporting (due to lack of strong evidence for higher categories)"
                }
            ],
            "final_evidence_strength": {
                "type": "Pathogenic",
                "strength": "PS3_supporting"
            },
            "overall_conclusion": "The functional evidence for LRRK2 R1441C is rated as PS3_supporting. The disease mechanism is well - defined, and the assay is applicable. Basic controls, replicates, and variant controls were used. Statistical analyses were done, but the lack of significant change in kinase activity results in a relatively low OddsPath value, supporting only a PS3_supporting level of pathogenic evidence."
        }
    ]
}